NCT01700673View on ClinicalTrials.gov

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.

BIOLOGICAL

Sargramostim

Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.

Trial Locations (1)

21287

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01700673 - Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | Biotech Hunter | Biotech Hunter